Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 4, 2010, Pages 531-539

  Terasaki, Yasuhiro ^a,d   Yahiro, Kinnosuke ^a,e   Pacheco Rodriguez, Gustavo ^a   Steagall, Wendy K ^a   Stylianou, Mario P ^a   Evans, Jilly F ^b   Walker, Ameae M ^c   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Amira Pharmaceuticals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e CHIBA UNIVERSITY   (Japan)

Author keywords

Pneumothorax; Proliferation; Pulmonary function tests; Tuberous sclerosis complex

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLACTIN; PROLACTIN RECEPTOR; PROTEIN P42; PROTEIN P44; STAT1 PROTEIN; STAT3 PROTEIN; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EMBRYO; EMBRYO CELL; ENZYME ACTIVATION; EXPLANT; FIBROBLAST; FORCED EXPIRATORY VOLUME; HORMONE ACTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PNEUMOTHORAX; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD; FEMALE; HUMAN; LUNG DISEASE; METABOLISM; METHODOLOGY; PATHOLOGY; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES; LYMPHANGIOLEIOMYOMATOSIS; MUSCLE, SMOOTH; PNEUMOTHORAX; PROLACTIN; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 77957062335     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200911-1737OC     Document Type: Article

References (42)

1. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006;27:1056-1065.
2. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Contr 2006;13:276-285.
3. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000;75:591-594. (Pubitemid 30395921)
4. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
5. Potter CJ, Huang H, Xu T. Drosophila tsc1 functions with tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
6. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24.
7. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002;277:30958-30967.
8. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106:2635-2640.
9. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev 2008;29:1-41.
10. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-1631.
11. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-669.
12. Vonderhaar BK. Prolactin involvement in breast cancer. Endocr Relat Cancer 1999;6:389-404.
13. Swaminathan G, Varghese B, Fuchs SY. Regulation of prolactin receptor levels and activity in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:81-91.
14. Steagall WK, Glasgow CG, Hathaway OM, Avila NA, Taveira-Dasilva AM, Rabel A, Stylianou MP, Lin JP, Chen X, Moss J. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007;293:L800-L808.
15. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998;95:15653-15658.
16. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997;99:618-627.
17. Tan D, Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, Vonderhaar BK, Walker AM. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homoand hetero-pairs of long and short human PRL receptors in living human cells. Mol Endocrinol 2005;19:1291-1303.
18. Walker AM. Therapeutic potential of S179D prolactin - from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin Investig Drugs 2006;15:1257-1267.
19. Huang K, Ueda E, Chen Y, Walker AM. Paradigm-shifters: phosphorylated prolactin and short prolactin receptors. J Mammary Gland Biol Neoplasia 2008;13:69-79.
20. Wu W, Ginsburg E, Vonderhaar BK, Walker AM. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res 2005;65:7509-7515. (Pubitemid 41161287)
21. Ueda EK, Lo HL, Bartolini P, Walker AM. S179D prolactin primarily uses the extrinsic pathway and mitogen-activated protein kinase signaling to induce apoptosis in human endothelial cells. Endocrinology 2006;147:4627-4637.
22. Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001;164:1072-1076.
23. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-221.
24. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004;64:6814-6819.
25. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000;21:292-312.
26. Dorshkind K, Horseman ND. Anterior pituitary hormones, stress, and immune system homeostasis. Bioessays 2001;23:288-294. (Pubitemid 32192148)
27. Horiguchi K, Yagi S, Ono K, Nishiura Y, Tanaka M, Ishida M, Harigaya T. Prolactin gene expression in mouse spleen helper T cells. J Endocrinol 2004;183:639-646.
28. Otte JM, Otte C, Beckedorf S, Schmitz F, Vonderhaar BK, Folsch UR, Kloehn S, Herzig KH, Monig H. Expression of functional prolactin and its receptor in human colorectal cancer. Int J Colorectal Dis 2003;18:86-94.
29. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-5560.
30. Gerlo S, Vanden Berghe W, Verdood P, Hooghe-Peters EL, Kooijman R. Regulation of prolactin expression in leukemic cell lines and peripheral blood mononuclear cells. J Neuroimmunol 2003;135:107-116.
31. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009;326:1216-1219.
32. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83:667-674.
33. Peirce SK, Chen WY. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol 2001;171:R1-R4.
34. Meng J, Tsai-Morris CH, Dufau ML. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Res 2004;64:5677-5682.
35. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003;144:5300-5307.
36. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, Tobe K, Matsuda S, Tsushima T, Yamamoto T, et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 2000;275:33937-33944.
37. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata: establishment and characterization of tumor-derived cell lines. Am J Pathol 1995;146:1568-1579.
38. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L. Signal transducer and activator of transcription (STAT) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 2001;155:531-542.
39. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-γ-JAK-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-γ treatment. Cancer Res 2004;64:3436-3443.
40. El-Hashemite N, Kwiatkowski DJ. Interferon-γ-JAK-STAT signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Respir Cell Mol Biol 2005;33:227-230. (Pubitemid 41254289)
41. Finlay GA, Thannickal VJ, Fanburg BL, Kwiatkowski DJ. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Cancer Res 2005;65:10881-10890.
42. Finlay GA, York B, Karas RH, Fanburg BL, Zhang H, Kwiatkowski DJ, Noonan DJ. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-b and ERK-1/2. J Biol Chem 2004;279:23114-23122.